Sven Lindemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sven Lindemann has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang Löscher
Translational Neuropharmacology Lab, NIFE, Department of Experimental Otology of the ENT Clinics Hannover Medical School Hannover Germany
5 shared publications Alina Lessenich
4 shared publications- Anne Gigout
Osteoarthritis Research, Merck KGaA, Darmstadt, Germany
4 shared publications - Anne-Christine Bay-Jensen
Nordic Bioscience, Herlev, Denmark
3 shared publications Mustapha Bennay
Department of Neuropharmacology, University of Bremen, Germany
3 shared publicationsWolfgang Löscher
3 shared publications
Latest Publications
- Open Access
Open Source Repurposing Reveals Broad-Spectrum Antiviral Activity of Diphenylureas
The pandemic threat from newly emerging viral diseases constitutes a major unsolved issue for global health. Antiviral therapy can play an important role in treating and preventing the spread of unprecedented viral infections. A repository of compounds exhibiting broad-spectrum antiviral activity against a series of different viral families would be an invaluable asset to be prepared for future pandemic threats. Utilizing an open innovation crowd-sourcing paradigm, we were able to identify a compound class of diphenylureas that exhibits in vitro antiviral activity against multiple viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), adenovirus, dengue virus, herpes, and influenza viruses. Compound 4 among the series exhibits strong activity against dengue virus, a growing global health problem with high medical need and no approved antiviral drug. The compounds are active against SARS-CoV-2 in a primary human stem cell-based mucociliary airway epithelium model and also active in vivo, as shown in a murine SARS-CoV-2 infection model. These results demonstrate the potential of the chemical class as antivirals on the one hand and the power of open innovation, crowd-sourcing, and repurposing on the other hand.
Open AccessOpen Source Repurposing Reveals Broad-Spectrum Antiviral Activity of Diphenylureas
The pandemic threat from newly emerging viral diseases constitutes a major unsolved issue for global health. Antiviral therapy can play an important role in treating and preventing the spread of unprecedented viral infections. A repository of compounds exhibiting broad-spectrum antiviral activity against a series of different viral families would be an invaluable asset to be prepared for future pandemic threats. Utilizing an open innovation crowd-sourcing paradigm, we were able to identify a compound class of diphenylureas that exhibits in vitro antiviral activity against multiple viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), adenovirus, dengue virus, herpes, and influenza viruses. Compound 4 among the series exhibits strong activity against dengue virus, a growing global health problem with high medical need and no approved antiviral drug. The compounds are active against SARS-CoV-2 in a primary human stem cell-based mucociliary airway epithelium model and also active in vivo, as shown in a murine SARS-CoV-2 infection model. These results demonstrate the potential of the chemical class as antivirals on the one hand and the power of open innovation, crowd-sourcing, and repurposing on the other hand.
- Open Access
- 20 December 2024
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 52 (1) , 1-12
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker
M6495 is a first-in-class NANOBODY® molecule and an inhibitor of ADAMTS-5, with the potential to be a disease modifying osteoarthritis drug. In order to investigate the PK/PD (pharmacokinetic and pharmacodynamic) properties of M6495, a single dose study was performed in cynomolgus monkeys with doses up to 6 mg/kg, with the goal of understanding the PK/PD properties of M6495. The neo-epitope ARGS (Alanine-Arginine-Glycine-Serine) generated by cleavage of aggrecan by ADAMTS-5 was used as a target-engagement biomarker. A long-lasting dose-dependent decrease in serum ARGS could be observed after a single dose of M6495 in cynomolgus monkeys. The serum biomarker ARGS decreased to levels below the limit of quantification of the assay in animals which received doses of M6495 of 6 mg/kg and higher, indicating a strong inhibition of ADAMTS-5. Data from the single-dose PK/PD study was combined with data from a multiple dose study, and a non-linear mixed effects model was used to explore the relationship between plasma concentrations of M6495 and the reduction of serum ARGS. The model was subsequently used to inform the clinical phase 1 study design and was successful in predicting the human clinical pharmacokinetics and pharmacodynamics of M6495. In addition to having enabled a Phase 1 trial with M6495, this is the first PK/PD model describing the pharmacodynamics of the neo-epitope ARGS after ADAMTS5 inhibition. It is expected that in the future, this model can be used or adapted to explore the PK/PD relationship between M6495 serum concentrations and the ARGS serum biomarker.
- 20 December 2024
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 52 (1) , 1-12
Open AccessTranslational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker
M6495 is a first-in-class NANOBODY® molecule and an inhibitor of ADAMTS-5, with the potential to be a disease modifying osteoarthritis drug. In order to investigate the PK/PD (pharmacokinetic and pharmacodynamic) properties of M6495, a single dose study was performed in cynomolgus monkeys with doses up to 6 mg/kg, with the goal of understanding the PK/PD properties of M6495. The neo-epitope ARGS (Alanine-Arginine-Glycine-Serine) generated by cleavage of aggrecan by ADAMTS-5 was used as a target-engagement biomarker. A long-lasting dose-dependent decrease in serum ARGS could be observed after a single dose of M6495 in cynomolgus monkeys. The serum biomarker ARGS decreased to levels below the limit of quantification of the assay in animals which received doses of M6495 of 6 mg/kg and higher, indicating a strong inhibition of ADAMTS-5. Data from the single-dose PK/PD study was combined with data from a multiple dose study, and a non-linear mixed effects model was used to explore the relationship between plasma concentrations of M6495 and the reduction of serum ARGS. The model was subsequently used to inform the clinical phase 1 study design and was successful in predicting the human clinical pharmacokinetics and pharmacodynamics of M6495. In addition to having enabled a Phase 1 trial with M6495, this is the first PK/PD model describing the pharmacodynamics of the neo-epitope ARGS after ADAMTS5 inhibition. It is expected that in the future, this model can be used or adapted to explore the PK/PD relationship between M6495 serum concentrations and the ARGS serum biomarker.
- Open Access
- 16 March 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (6) , 1002-1011
Target 2035 – an update on private sector contributions
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.
- 16 March 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (6) , 1002-1011
Open AccessTarget 2035 – an update on private sector contributions
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.
- Open Access
- 3 December 2021
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13 (1) , 13-21
Target 2035 – update on the quest for a probe for every protein
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. Target 2035 aims to develop a pharmacological modulator for every protein in the human proteome to fill this gap.
- 3 December 2021
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13 (1) , 13-21
Open AccessTarget 2035 – update on the quest for a probe for every protein
Twenty years after the publication of the first draft of the human genome, our knowledge of the human proteome is still fragmented. Target 2035 aims to develop a pharmacological modulator for every protein in the human proteome to fill this gap.
- Open Access
- 14 August 2021
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 3 (4) , 100207
A serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis
- 14 August 2021
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 3 (4) , 100207
Open AccessA serological type II collagen neoepitope biomarker reflects cartilage breakdown in patients with osteoarthritis
- 1 May 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (5) , 658-668
Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors
- 1 May 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (5) , 658-668
Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors
- Open Access
- 14 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 531
Increasing the Medium Osmolarity Reduces the Inflammatory Status of Human OA Chondrocytes and Increases Their Responsiveness to GDF-5
The environment surrounding chondrocytes changes drastically in osteoarthritis (OA). For instance, the osmolarity in cartilage (ranging from 350 to 460 mOsm in healthy tissue) decreases during the progression of OA, reaching 270 mOsm. The objective of this study was to evaluate how osmolarity influences human OA chondrocytes. For this purpose, the osmolarity of the culture medium (340 mOsm) was increased to 380, 420 or 460 mOsm and its effect on the phenotype, matrix production, protease expression, cytokine release and growth and differentiation factor-5 (GDF-5) receptor expression in human OA chondrocytes was evaluated in a monolayer. Afterwards, the same parameters, as well as the responsiveness to GDF-5, were evaluated in 3D culture at 340 and 380 mOsm. Our results revealed that increasing the medium osmolarity increased matrix production but also reduced cytokine release, type I collagen and protease expression. It was also demonstrated that at 380 mOsm, the response to GDF-5 in 3D culture was more robust than at 340 mOsm. For the first time, it was established that a decreased osmolarity plays a role in sustaining inflammation and catabolic activities in OA chondrocytes and decreases their responsiveness to GDF-5. This indicates that osmolarity is a critical aspect of OA pathobiology.
- 14 January 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (2) , 531
Open AccessIncreasing the Medium Osmolarity Reduces the Inflammatory Status of Human OA Chondrocytes and Increases Their Responsiveness to GDF-5
The environment surrounding chondrocytes changes drastically in osteoarthritis (OA). For instance, the osmolarity in cartilage (ranging from 350 to 460 mOsm in healthy tissue) decreases during the progression of OA, reaching 270 mOsm. The objective of this study was to evaluate how osmolarity influences human OA chondrocytes. For this purpose, the osmolarity of the culture medium (340 mOsm) was increased to 380, 420 or 460 mOsm and its effect on the phenotype, matrix production, protease expression, cytokine release and growth and differentiation factor-5 (GDF-5) receptor expression in human OA chondrocytes was evaluated in a monolayer. Afterwards, the same parameters, as well as the responsiveness to GDF-5, were evaluated in 3D culture at 340 and 380 mOsm. Our results revealed that increasing the medium osmolarity increased matrix production but also reduced cytokine release, type I collagen and protease expression. It was also demonstrated that at 380 mOsm, the response to GDF-5 in 3D culture was more robust than at 340 mOsm. For the first time, it was established that a decreased osmolarity plays a role in sustaining inflammation and catabolic activities in OA chondrocytes and decreases their responsiveness to GDF-5. This indicates that osmolarity is a critical aspect of OA pathobiology.
- Open Access
- 1 November 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25 (11) , 1858-1867
Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix
- 1 November 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25 (11) , 1858-1867
Open AccessSprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix
- 1 April 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25, S154-S155
A strong correlation – influence of medium osmolarity on “chondrocyte health”
- 1 April 2017
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 25, S154-S155
A strong correlation – influence of medium osmolarity on “chondrocyte health”